In particular, α6β4, αvβ3, and β1-type integrins have been shown to contribute to breast cancer metastasis to the CNS [28,29,30] and to other organs [31,32,33,34], to regulate cancer stem-cell phenotypes [35,36] and to mediate the resistance to systemic chemotherapy and EGFR/HER2-targeting therapies [27,37,38]. Here, ERBB2 is linked to breast carcinoma.